Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Top Cited Papers
- 14 January 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (2), 129-139
- https://doi.org/10.1056/nejmoa2030186
Abstract
The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied.Keywords
Funding Information
- Sanofi
- LEXICON
This publication has 49 references indexed in Scilit:
- Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 DiabetesDiabetes Care, 2015
- Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trialsThe Lancet Diabetes & Endocrinology, 2015
- Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 TrialDiabetes Care, 2014
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized TrialCirculation, 2014
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusThe New England Journal of Medicine, 2013
- Clopidogrel with or without Omeprazole in Coronary Artery DiseaseThe New England Journal of Medicine, 2010
- Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With AtherothrombosisJAMA, 2010
- One-Year Cardiovascular Event Rates in Outpatients With AtherothrombosisJAMA, 2007
- International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With AtherothrombosisJAMA, 2006
- Standardized rates of recurrent outcomesStatistics in Medicine, 1994